Conversion to sirolimus in kidney transplant recipients with squamous cell cancer and changes in immune phenotype

Nephrology Dialysis Transplantation

Volumn 28, Issue 2, 2013, Pages 462-465

  Carroll, Robert P ^a,b,c   Hester, Joanna ^a   Wood, Kathryn J ^a   Harden, Paul N ^c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b Central and Northern Adelaide Renal and Transplantation Service   (Australia)

^c CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

immune phenotype; mTOR inhibitors; skin cancer; Treg

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID; PREDNISOLONE; RAPAMYCIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HUMAN; IMMUNOPHENOTYPING; KIDNEY TRANSPLANT RECIPIENT; KIDNEY TRANSPLANTATION; LYMPHOCYTE COUNT; MALE; NATURAL KILLER CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE; UNSPECIFIED SIDE EFFECT;

AGED; AGED, 80 AND OVER; ANTIGENS, CD56; AZATHIOPRINE; CALCINEURIN; CARCINOMA, SQUAMOUS CELL; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; PHENOTYPE; RISK FACTORS; SINGLE-BLIND METHOD; SIROLIMUS; SKIN NEOPLASMS; T-LYMPHOCYTES; TOR SERINE-THREONINE KINASES; TRANSPLANTATION;

EID: 84874539439     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs474     Document Type: Article

References (20)

1. Mathew T, Kreis H, Friend P. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin Transplant 2004; 18: 446-449 (Pubitemid 39077081)
2. Campistol JM, Eris J, Oberbauer R et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 2006; 17: 581-589
3. Alberu J, Pascoe MD, Campistol JM et al. Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial. Transplantation 2011; 92: 303-310
4. Guba M, Graeb C, Jauch K-W et al. Pro-and anti-cancer effects of immunosuppressive agents used in organ transplantation. Transplantation 2004; 77: 1777-1782 (Pubitemid 38822196)
5. Guba M, von Breitenbuch P, Steinbauer M et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8: 128-135 (Pubitemid 34155123)
6. Koehl GE, Andrassy J, Guba M et al. Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation 2004; 77: 1319-1326 (Pubitemid 38668421)
7. Beuvink I, Boulay A, Fumagalli S et al. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 2005; 120: 747-759 (Pubitemid 40568794)
8. Dantal J, Hourmant M, Cantarovich D et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998; 351: 623-628 (Pubitemid 28098444)
9. Otley CC, Coldiron BM, Stasko T et al. Decreased skin cancer after cessation of therapy with transplant-associated immunosuppressants. Arch Dermatol 2001; 137: 459-463 (Pubitemid 32319841)
10. Campbell SB, Walker R, Tai SS et al. Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer. Am JTransplant 2012; 12: 1146-1156
11. Schena FP, Pascoe MD, Alberu J et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009; 87: 233-242
12. Ekberg H, Tedesco-Silva H, Demirbas A et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562-2575 (Pubitemid 350294223)
13. Frei U, Daloze P, Vitko S et al. Acute rejection in low-toxicity regimens: clinical impact and risk factors in the Symphony study. Clin Transplant 2010; 24: 500-509
14. Ducloux D, Carron PL, Rebibou JM et al. CD4 lymphocytopenia as a risk factor for skin cancers in renal transplant recipients. Transplantation 1998; 65: 1270-1272 (Pubitemid 28224350)
15. Thibaudin D, Alamartine E, Mariat C et al. Long-term kinetic of Tlymphocyte subsets in kidney-transplant recipients: influence of anti-T-cell antibodies and association with posttransplant malignancies. Transplantation 2005; 80: 1514-1517 (Pubitemid 41803636)
16. Carroll RP, Segundo DS, Hollowood K et al. Immune phenotype predicts risk for posttransplantation squamous cell carcinoma. J Am Soc Nephrol 2010; 21: 713-722
17. Baan CC, van der Mast BJ, Klepper M et al. Differential effect of calcineurin inhibitors, anti-CD25 antibodies and rapamycin on the induction of FOXP3 in human T cells. Transplantation 2005; 80: 110-117 (Pubitemid 40980903)
18. San Segundo D, Fabrega E, Lopez-Hoyos M et al. Reduced numbers of blood natural regulatory T cells in stable liver transplant recipients with high levels of calcineurin inhibitors. Transplant Proc 2007; 39: 2290-2292 (Pubitemid 47418222)
19. Segundo DS, Ruiz JC, Izquierdo M et al. Calcineurin inhibitors, but not rapamycin, reduce percentages of CD4+CD25+FOXP3+ regulatory T cells in renal transplant recipients. Transplantation 2006; 82: 550-557 (Pubitemid 44290262)
20. Vandenbroucke JP, von Elm E, Altman DG et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Ann Intern Med 2007; 147: W163-W194 (Pubitemid 351664503)